A Clinical Guide to Peptide Receptor Radionuclide Therapy with (177)Lu-DOTATATE in Neuroendocrine Tumor Patients

SIMPLE SUMMARY: Peptide receptor radionuclide therapy (PRRT) is one of the treatment options for locally advanced or metastatic gastroenteropancreatic (GEP) neuroendocrine tumors (NETs). This treatment makes use of radioactive labeled somatostatin analogues, with (177)Lu-DOTATATE as its established...

Descripción completa

Detalles Bibliográficos
Autores principales: Becx, Morticia N., Minczeles, Noémie S., Brabander, Tessa, de Herder, Wouter W., Nonnekens, Julie, Hofland, Johannes
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9737149/
https://www.ncbi.nlm.nih.gov/pubmed/36497273
http://dx.doi.org/10.3390/cancers14235792

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9737149/
https://www.ncbi.nlm.nih.gov/pubmed/36497273
http://dx.doi.org/10.3390/cancers14235792

Ejemplares similares